Amira Pharmaceuticals and GSK, global agreement for FLAP inhibitor programme

4-February-2008: Amira Pharmaceuticals and GlaxoSmithKline enter global agreement for FLAP inhibitor program. Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory diseaseAmira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein¬) inhibitors for the treatment of respiratory and cardiovascular disease... Amira Pharmaceuticals' Press Release - GlaxoSmithKline's Press Release -